Target Price | JPY2,958.00 |
Price | JPY2,075.00 |
Potential |
42.55%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Zeria Pharmaceutical 2026 .
The average Zeria Pharmaceutical target price is JPY2,958.00.
This is
42.55%
register free of charge
JPY3,045.00
46.75%
register free of charge
JPY2,929.00
41.16%
register free of charge
|
|
A rating was issued by 5 analysts: 4 Analysts recommend Zeria Pharmaceutical to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Zeria Pharmaceutical stock has an average upside potential 2026 of
42.55%
register free of charge
|
Mar '25 |
2026 Estimates |
|
---|---|---|
Revenue Billion JPY | 87.31 | 92.92 |
15.30% | 6.42% | |
EBITDA Margin | 20.67% | 22.17% |
4.76% | 7.25% | |
Net Margin | 11.38% | 10.76% |
11.47% | 5.45% |
2 Analysts have issued a sales forecast Zeria Pharmaceutical 2026 . The average Zeria Pharmaceutical sales estimate is
This results in the following potential growth metrics:
2 Zeria Pharmaceutical Analysts have issued a net profit forecast 2026. The average Zeria Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Mar '25 |
2026 Estimates |
|
---|---|---|
Earnings Per Share JPY | 225.42 | 226.85 |
28.53% | 0.63% | |
P/E | 9.06 | |
EV/Sales | 1.17 |
2 Analysts have issued a Zeria Pharmaceutical forecast for earnings per share. The average Zeria Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Zeria Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.